C4 Therapeutics has been granted a patent for cereblon binders that can degrade Ikaros or Aiolos proteins through the ubiquitin proteasome pathway. These compounds have potential therapeutic applications in treating various medical disorders, including cancer. GlobalData’s report on C4 Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights C4 Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on C4 Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. C4 Therapeutics's grant share as of September 2023 was 11%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11753397B2) discloses a compound that has potential applications in the field of pharmaceuticals. The compound is selected from various formulas and can be further modified based on specific criteria outlined in the claims.

The compound described in claim 1 is characterized by its structure and can be represented by different formulas. In claim 2, it is specified that the compound has a specific value for the variable "m," which is 0. Claim 3 provides further details about the compound, stating that it contains a heterocycle group that can be substituted with various substituents, such as alkyl, alkenyl, alkynyl, halogen, cyano, heteroaryl, aryl, cycloalkyl, and others. Importantly, the substituents should not form N—O or N—N bonds.

Claims 4, 5, and 6 specify additional formulas for the compound, highlighting its structural variations. Claim 7 broadens the scope by stating that the compound can be selected from a range of possibilities. In claims 8 to 12, specific substituents for the variable "R5" are outlined, including alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, cyano, halogen, —OR2, and —NR2R2. These substituents can be present in different quantities.

Claim 13 specifies that the compound can have the substituent —OR2. In claim 14, the variable "x" can have a value of 0, 1, or 2. Claim 15 states that the variable "R13" is alkyl. Claims 16 and 17 reiterate the selection of compounds from the previously mentioned formulas.

The patent also covers the use of the compound in pharmaceutical compositions. Claim 18 states that the compound can be combined with a pharmaceutically acceptable carrier or diluent to form a pharmaceutical composition. Finally, claim 19 provides a specific formula for the compound.

Overall, this granted patent discloses a compound with various structural variations and substituents, which can be used in pharmaceutical compositions. The patent provides specific criteria for the compound's structure and substituents, allowing for potential applications in the development of new drugs.

To know more about GlobalData’s detailed insights on C4 Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies